Clinical and pathological characteristics of patients in relation to metastasis-free survival (MFS).

<p>Clinical and pathological characteristics of patients in relation to metastasis-free survival (MFS).</p

Relationship between <i>AHR</i> mRNA expression and classical clinical and pathological parameters in a series of 439 breast cancers.

<p>Relationship between <i>AHR</i> mRNA expression and classical clinical and pathological parameters in a series of 439 breast cancers.</p

mRNA expression levels of <i>AHR</i>, <i>AHRR</i> and <i>ARNT</i>, and of genes involved in inflammation, in MDA-MB-436 breast cancer cell line treated with two different <i>AHR</i> ligands.

<p>MDA-MB-436 cells were cultivated in absence (CTL) or in presence of TCDD (2,3,7,8-tetrachlorodibenzo-p-dioxin) (10^-9M) or BaP (benzo[a]pyrene) (10^-6M) for 16 h. Cells were then lysed and mRNA extracted. mRNA expression levels of <i>AHR</i>, <i>AHRR</i> and <i>ARNT</i> (A), and of <i>IL1B</i>, <i>IL6</i>, <i>IL8</i> and <i>CXCR4</i> (B) were determined by qRT-PCR. All experiments were performed in triplicate. Results were expressed as mean +/- s.e.m and normalized so that the mean of the control cells was 1. Three levels of statistical significance are distinguished: *p-value<0.05; **p-value<0.01; ***p-value<0.001.</p

Survival curves of two groups of patients according to <i>AHRR</i> mRNA expression level in the cohort of 439 breast tumors.

<p>AUC analysis was used to divide the population into two relevant <i>AHRR</i> expression subgroups.</p

Relationship between <i>AHRR</i> mRNA expression and classical clinical and pathological parameters in a cohort of 439 breast cancers.

<p>Relationship between <i>AHRR</i> mRNA expression and classical clinical and pathological parameters in a cohort of 439 breast cancers.</p

Immunocytochemical staining for AhR and CD4 in breast tumors.

<p><b>a-b</b>, moderate AhR-expressing tumor cells. Note positive AhR staining in the intratumoral stroma. <b>c-d</b>, immunostaining for AhR (c) or CD4 (d) in the same tumor sample. Immunostaining for both AhR and CD4 is observed in stromal cells in the intratumoral compartment. T, tumor cells; S, intratumoral stroma. Original Magnification, x 20.</p

List of the 55 selected genes tested.

<p>List of the 55 selected genes tested.</p

RelA knock-down by RNAi blocks TNFα-induced gene expression in HMEC cells.

<p>(A) Nuclear extracts from HMEC cells treated with TNF-α for the indicated periods of time were analyzed by EMSA using a ³²P-labeled HIV-LTR tandem κB oligonucleotide as a probe. (B) For supershift, nuclear extracts from HMEC cells treated with TNFα for 4 hours were incubated with the indicated antibodies before incubation with the labeled probe. Complex I: RelA/p50. (C) Nuclear extracts from HMEC cells stably transduced with a lentivirus encoding a shRNA targeting either RelA or a scrambled control, and treated by TNFα for the indicated periods of time were analyzed by EMSA as described in (A).</p

Kinetics of selected NFkB gene expression in TNF-α treated HMEC.

a<p>Ratio of the mRNA content in cells stimulated with TNF-α (40 ng/ml) for 2, 8, 15, 30 min or 1, 4, 24 and 72 h to the mRNA content in the control cell.</p

Relationship between expression of <i>TNF</i> and expression of the 19 others identified putative TNF-inducible genes in 48 REα negative breast tumors and 48 REα positive breast tumors.

<p><b>^a</b>Spearman correlation coefficient. <b>^b</b>P value, Spearman rank correlation test.</p><p><b>NS</b>, not significant.</p